2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.
Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.
These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.
Here’s what you may have missed:
Efficacy of Imetelstat Plus Ruxolitinib in Higher-Risk Myelofibrosis: John O. Mascarenhas, MD
John O. Mascarenhas, MD, of the Icahn School of Medicine at Mount Sinai, discusses preliminary findings from the phase 1/1b IMproveMF trial (NCT05371964) evaluating imetelstat (Rytelo) plus ruxolitinib (Jakafi) in patients with intermediate- to high-risk myelofibrosis. Early results showed clinical improvements, including spleen volume response, symptom reduction, and decreases in driver mutations such as JAK2, CALR, and high-risk mutations like ASXL1. Mascarenhas noted that these are the first data to demonstrate tolerability and potential disease modification with the combination in earlier treatment settings. He added that the ongoing evaluation will focus on marrow response, mutational burden, and longer-term outcomes, with part 2 of the study now enrolling JAK inhibitor–naive patients to assess the combination in the frontline setting.
FDA Approval of Dato-DXd for Advanced/Metastatic EGFR-Mutated NSCLC: Balazs Halmos, MD
Balazs Halmos, MD, of Montefiore Einstein Comprehensive Cancer Center and Albert Einstein College of Medicine, discusses the FDA’s accelerated approval of datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) for patients with previously treated, i-mutated non–small cell lung cancer (NSCLC). The approval was based on data from the TROPION-Lung05 (NCT04484142) and TROPION-Lung01 (NCT04656652) trials, in which Dato-DXd demonstrated a 45% overall response rate and a median duration of response of 6.5 months in this population. Halmos emphasized that the agent offers a valuable option for patients who have progressed on both EGFR-targeted therapies and chemotherapy, a setting with limited treatment alternatives. He added that while adverse effects, such as stomatitis and interstitial lung disease, require monitoring, the safety profile is manageable, and the observed activity reinforces Dato-DXd’s role in the EGFR-mutated NSCLC treatment sequence.
Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer:Alexander B. Olawaiye, MD
Alexander B. Olawaiye, MD, of the University of Pittsburgh and Magee-Women’s Hospital, discusses the clinical relevance of the phase 3 ROSELLA trial (NCT05257408), which evaluated relacorilant plus nab-paclitaxel (Abraxane) in patients with platinum-resistant ovarian cancer. At the 2025 ASCO Annual Meeting, interim data showed the combination significantly improved overall survival vs nab-paclitaxel alone, with a median OS of 15.97 vs 11.50 months, respectively (HR, 0.69; P = .0121). Olawaiye highlighted that this regimen does not require biomarker testing, allowing broad eligibility for patients with platinum-resistant disease who have received prior treatment. He added that relacorilant is an oral agent, making the combination both accessible and convenient for clinical use.
Ribociclib Plus Endocrine Therapy in Premenopausal HR+/HER2-Negative Advanced Breast Cancer: Nagi S. El-Saghir, MD, FACP, FASCO
Nagi S. El-Saghir, MD, FACP, FASCO, of the American University of Beirut Medical Center, discusses subgroup data from the phase 2 RIGHT Choice trial (NCT03839823), which evaluated ribociclib (Kisqali) plus endocrine therapy vs combination chemotherapy in premenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer. At the 2025 ASCO Annual Meeting, findings showed that patients with liver metastases had a median progression-free survival (PFS) of 18.3 months with ribociclib plus endocrine therapy vs 12.7 months with chemotherapy, and those without liver metastases experienced a median PFS of 25.2 vs 15.4 months, respectively. El-Saghir emphasized that patients with visceral and symptomatic disease—including liver metastases—benefited from the ribociclib-based regimen, which also yielded favorable quality-of-life outcomes. These findings support ribociclib plus endocrine therapy and ovarian function suppression as a viable, less toxic frontline alternative to chemotherapy in this high-risk population.
Treatment Gaps With Immunotherapy in Melanoma: Douglas B. Johnson, MD
Douglas B. Johnson, MD, MSCI, of Vanderbilt University Medical Center, discusses persistent challenges in frontline and salvage immunotherapy for melanoma. At the 2025 ASCO Annual Meeting, he noted that although checkpoint inhibitors have transformed care, response rates in the first-line setting remain between 10% and 30%, with approximately half of patients deriving limited or no benefit. Johnson highlighted emerging strategies for refractory disease, including tumor-infiltrating lymphocyte therapy—such as lifileucel (Amtagvi)—and investigational T-cell receptor therapies like IMA203, which is under evaluation in the phase 3 SUPRAME trial (NCT06743126). He emphasized the need for predictive biomarkers and more effective therapies to improve outcomes for patients who progress after standard immunotherapy.
Related Content: